African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2288

Full Length Research Paper

Pharmacokinetics of isoniazid in 30 tuberculosis patients in Abidjan, Côte d'Ivoire

Djadji A. T. L. *
  • Djadji A. T. L. *
  • Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Kouakou A. F.
  • Kouakou A. F.
  • Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Kamagate M.
  • Kamagate M.
  • Laboratory of Clinical Pharmacology, Faculty of Medicine Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Siransy-Kouakou G.
  • Siransy-Kouakou G.
  • Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Bekegnran C.
  • Bekegnran C.
  • Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Abrogoua D. P.
  • Abrogoua D. P.
  • Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Kablan B. J.
  • Kablan B. J.
  • Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Die-Kacou H.
  • Die-Kacou H.
  • Laboratory of Clinical Pharmacology, Faculty of Medicine Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Eholie S. P.
  • Eholie S. P.
  • Department of Infectious and Tropical Diseases, Faculty of medicine Felix Houphouet Boigny?s University, Abidjan.
  • Search for this author on:
  • Google Scholar
Garraffo R.
  • Garraffo R.
  • Department of Clinical Pharmacology and medical Toxicology, Hospital Pasteur, Nice France.
  • Search for this author on:
  • Google Scholar


  •  Received: 10 April 2014
  •  Accepted: 02 March 2015
  •  Published: 29 July 2015

References

Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda (2003). Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. Gastroenterol Hepatol. 28(2):323-328.
crossref
 
Cho H, Koh W, Ryu Y, Ki C, Nam M, Kim J, Lee S (2007). Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 87 551–556.
crossref
 
Des Prez R, Boone IU (1961). Metabolism of C14-isoniazid in humans. Am. Rev. Respir. Dis. 84:42–51.
Pubmed
 
Elmendorf DF, Cawthon WU, Muschenheim C, McDermott W (1952). The absorption, distribution, excretion, and short-term toxicity of isonicotinic acid hydrazide (hydrazid) in man. Am. Rev. Tuberc. 65:429–442.
Pubmed
 
Hoin G (1999). Pharmacocinétique, support de l'enseignement de la pharmacologie générale Associations des enseignants de Pharmacologie des UFR de Pharmacie Ellipse pp. 55-125. http://www.who.int/tb/challenges/gender/page_1/fr/index.html http://www.who.int/tb/challenges/hiv/fr/
 
Justin J Wilkins, Grant Langdon, Helen McIlleron, Goonaseelan Pillai, Peter J Smith, and Ulrika S H Simonsson (2011). Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br. J. Clin. Pharmacol. 72:1.
 
Kergueris MF, Bourin M, Larousse C (1986). Pharmacokinetics of isoniazid: influence of age. Eur. J. Clin. Pharmacol. 30(3):335-340.
crossref
 
Marquet P (2004). Suivi thérapeutique pharmacologique pour l'adaptation de posologie des médicaments Paris: Elsevier, pp. 97-104.
 
McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P (2006). Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrobiol. Agents Chemother. 50:170–177.
crossref
 
Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der walt BJ, Donald PR, van Jaarsveld PP (1997). Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Me. 155:1717–1722.
crossref
 
Peloquin CA (2002). Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169–2183.
crossref
 
Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, Santos AR, Teixeira RLF, Gregianini TS, Hutz MH, Rossetti MLR, Zaha A (2008). Association of slow N- acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol. 64:673–681.
crossref
 
Prema G, Geetha R AK, Hemanth K, Rajasekaran S (2004). Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 38(2):80-283.
 
Québec (2009). Center of expertise in environnemental analyse Québec 2009. Protocole pour la validation d'une méthode d'analyse en chimie, DR-12-VMC, Québec, Programme d'accréditation des laboratoires d'analyses, Édition juin.
 
Rey E, Gendrel D, Treluyer JM, Tran A, Pariente-Khayat A, d'Athis P, Pons G (2001). Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam. Clin. Pharmacol. 15(5):355-359.
crossref
 
Rey E, Pons G, Crémier O, Vauzelle-Kervroëdan F, Pariente-Khayat A, d'Athis P, Badoual J, Olive G, Gendrel D (1998). Isoniazid dose adjustment in a pediatric population. Ther. Drug Monit. 20(1):50-55.
crossref
 
Rohit B, Indu PK (2012). A sensitive hplc method for determination of Isoniazid in Rat Plasma, Brain, Liver and Kidney. J. Chromat. Separation Techniq. 3:3.
 
Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS(2011). Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: Evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 55(12):5560-5567.
crossref
 
Vivien JN, Thibier R, Lepeuple A (1973). La pharmacocinétique de l'isoniazide dans la race blanche. Rev Fr Mal Respiratoire. 1:753-773.
 
World Health Organization (WHO) (2009). Treatment of Tuberculosis: Guidelines. WHO/HTM/TB/2009 420, 4th edn. Geneva: World, Health Organization.
 
World Health Organization (WHO) (2010). Global Tuberculosis Control: WHO Report 2010. WHO/HTM/TB/2010.7. Geneva: World Health Organization.

 

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 9 No. 28
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES